Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · melanoma-umap@29

SRR2771207

—

d27f4008-b725-5c32-8e86-310c237d2f7b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.500
  • APICAL_JUNCTION+0.400
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
  • MYC_TARGETS_V2+0.400
  • NOTCH_SIGNALING+0.400
  • E2F_TARGETS+0.300
  • HYPOXIA+0.300
  • UV_RESPONSE_UP+0.300
  • WNT_BETA_CATENIN_SIGNALING+0.300
  • APICAL_SURFACE+0.200

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.300
  • PROTEIN_SECRETION-0.300
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • INTERFERON_GAMMA_RESPONSE-0.100
  • ALLOGRAFT_REJECTION+0.000
  • ANDROGEN_RESPONSE+0.000
  • BILE_ACID_METABOLISM+0.000
  • COMPLEMENT+0.000
  • ESTROGEN_RESPONSE_EARLY+0.000
  • ESTROGEN_RESPONSE_LATE+0.000

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-34-5236-01A-21R-1820-07
lung-landscapes@6
—cohortSQ10.854
2SRR12475169
colon-landscapes@1
——0.836
3C3N-01892
lung-landscapes@6
—cohortSQ10.820
4SRR27320688
colon-landscapes@1
——0.816
5SRR8526723
lung-landscapes@6
—cohortA10.813
6BS_QP6MSKRE
brain-umap@2
Spinal Cord Ependymoma—0.811
7TCGA-A7-A6VV-01A-22R-A33J-07
breast-umap@18
—E0.809
8TCGA-A7-A13D-01A-13R-A12P-07
breast-umap@18
—E0.802
9MNG1297
mng-umap@100
——0.796
10MBCProject_2290_T2_RNA
breast-umap@18
—E0.784

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 32 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.500Remibrutinib— uncovered
APICAL_JUNCTION0.400Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.400Inavolisib— uncovered
MYC_TARGETS_V20.400Idelalisib— uncovered
NOTCH_SIGNALING0.400Inavolisib— uncovered
E2F_TARGETS0.300Inavolisib— uncovered
HYPOXIA0.300Idelalisib— uncovered
UV_RESPONSE_UP0.300Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.300Inavolisib— uncovered
APICAL_SURFACE0.200Temsirolimus— uncovered
G2M_CHECKPOINT0.200Inavolisib— uncovered
GLYCOLYSIS0.200Inavolisib— uncovered
HEDGEHOG_SIGNALING0.200Inavolisib— uncovered
IL2_STAT5_SIGNALING0.200Idelalisib— uncovered
MTORC1_SIGNALING0.200Inavolisib— uncovered
MYC_TARGETS_V10.200Inavolisib— uncovered
MYOGENESIS0.200Inavolisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.200Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered